Knowledge Network Node

Double-blind Control Treatment of Huperzine-A and Placebo in 28 Patients with Alzheimer DiseaseCN

Liu Fugen, Fang Yongshen, Gao Zhixu, Zuo Jindi, Sou Meilan Shanghai Mental Health Center, Shanghai 200030, P.R.China

Abstract:A comparative study of therapeutic effect between home-made Huperzine-A tablet and placebo was conducted in 28 patients with Alzheimer diseases (AD). 28 patients were e-qually divided into two groups at random. The first group received Huperzine-A tablet and the other group was given placebo. The courses of treatment for two groups last for 60 days. The average doses for both groups were 600 μg/day. There were no significant differences in sex, age between two groups (P>0. 05). After treatment, mean scale score of Huperzine-A group was higher than the placebo group in HDS and MMSE. Moreover, the mean scale score in ADL of Huperzine-A group was lower than that in placebo group. No side effect was observed. It is suggested that Huperzine-A tablet was effective and safe for AD. The tablet of Huperzine-A was more convenient for clinical use in the AD patients.
  • Series:

    (E) Medicine & Public Health

  • Subject:

    Psychiatry

  • Classification Code:

    R749.1

  • Mobile Reading
    Read on your phone instantly
    Step 1

    Scan QR Codes

    "Mobile CNKI-CNKI Express" App

    Step 2

    Oper“CNKI Express”

    and click the scan icon in the upper left corner of the homepage.

    Step 3

    Scan QR Codes

    Read this article on your phone.

  • CAJ Download
  • PDF Download

Download the mobile appuse the app to scan this coderead the article.

Download:135 Page No:196-198 Page:3 Size:138k

Related Literature
  • Similar Article
  • Reader Recommendation
  • Related Funding Articles
  • Associated Author